RxDoctor Payments Data

Victor Flores Cheverez, MD

Nephrology · San Juan, PRNPI 1265401590

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 39.8% of the total. Reporting peaked in 2019 at $987 and has fallen 84.6% since, to $152 in 2025.

$3,168in general payments, 2019–2025

Across 36 payments — averaging $88.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Nxstage Medical, Inc.$339
  • E.r. Squibb & Sons, L.L.C.$221
  • GSK$157
  • Fresenius USA Marketing, Inc.$149
  • Travere Therapeutics, Inc.$149
  • plus $891 from 8 others

What the payments were for

  • Food & beverage$3,07797%
  • Education$913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,168 in reported general payments places this provider in the 75th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$21,901
Medicare patients
49
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate74$61,450
KerendiaFinerenone64$43,628
FarxigaDapagliflozin Propanediol62$38,641
Sevelamer Carbonate77$9,939
Calcium Acetate40$4,243
Sodium Polystyrene Sulfonate19$1,874
Candesartan Cilexetil14$835
Allopurinol110$791
Enalapril Maleate13$465
Losartan Potassium40$452
Calcitriol22$342
Amlodipine Besylate50$237
Clonidine Hcl32$226
Hydrochlorothiazide32$221
Carvedilol27$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$1,262$100,092136 claims
BayerKerendia$142$43,62864 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →